Blood Group Typing Market

The global blood group typing market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $3.0 billion by 2028, growing at a CAGR of 8.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The increasing frequency of road accidents contributes to the expansion of the market. Road accidents and trauma can lead to physical injuries, hemorrhagic shock, and chronic anemia, which can require major surgeries. The urgent need for blood transfusion in patients requiring immediate surgical intervention may affect the performance of testing, resulting in inadequate and incompatible blood transfusion. Compatibility testing is performed before a blood transfusion to check the compatibility of donor and recipient blood to prevent erroneous blood transfusions.

Attractive Opportunities in the Blood Group Typing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Blood Group Typing Market Dynamics

DRIVER: The increasing prevalence of chronic diseases and the rising number of surgical procedures necessitate the need for blood donations

With the growth in the prevalence of chronic diseases and surgical procedures for their treatment, the demand for blood has increased. Patients with chronic conditions often require regular blood transfusions to manage their conditions, while surgical procedures, especially major surgeries, necessitate significant amounts of blood for safe and successful outcomes. Consequently, the healthcare system has seen a steady rise in the need for blood, prompting a corresponding increase in blood donations. This is expected to positively impact the market. According to the American National Red Cross (2023), approximately 29,000 units of red blood cells are needed every day in the US in hospitals and emergency treatment facilities to treat patients suffering from chronic diseases and patients undergoing complex surgical procedures. According to the same source, ~16 million units of blood components are transfused in the US in a year.

RESTRAINT: Emergence of blood alternatives

The search for blood substitutes is not new. There already exists factor concentrates to replace fresh-frozen plasma. Although oxygen carriers in the form of perfluorocarbons have not been successful on a large scale, cultured RBCs & platelets can still replace allogeneic platelets and red cells.

Research has shown proof that red cells can be generated from stem cells. In vitro, the generation of RBCs or cultured RBCs (cRBCs) from pluripotent stem cells remains a distinct possibility. If this happens, the concepts of voluntary blood donation, blood testing, and the use of pathogen inactivation by blood centers will all become redundant. There will be minimal need for grouping, cross-matching, and testing.

OPPORTUNITY: Growth opportunities in emerging economies

Emerging economies such as South Korea, Malaysia, Vietnam, Africa, and Middle Eastern countries like Israel, Saudi Arabia, and the UAE offer significant growth opportunities to major market players operating in the market. This can be attributed to the healthcare infrastructural improvements in these countries, the growing patient population, and the rising healthcare expenditure.

Moreover, the disposable income of populations in developing and emerging countries is on the rise. This increase is another key indicator of expanding access to healthcare. According to the OECD, the purchasing power of the growing middle-class population is expected to increase to 59% by 2020 from 23% in 2009. According to the Ministry of Statistics and Programme Implementation (MOSPI), the total Gross National Disposable Income (GNDI) in India increased to USD 20,769.9 million (INR 1,538,430 million) per capita in 2019–2020. With rising disposable incomes and the increasing medical needs of the middle-class population, blood group typing product manufacturers are compelled to devise new strategies to meet this demand. Currently, emerging markets are underpenetrated by major players, which indicates a huge untapped market potential.

Blood Group Typing Ecosystem/Market Map

Consumables segment accounted for the largest share of the blood group typing industry in 2022, by product & service.

The blood group typing market is categorized into consumables, instruments, and services & software based on product & service. The consumables segment emerged as the dominant force in the market in 2022. The recurring cost associated with the frequent requirement of reagents & kits is a significant factor contributing to the market's growth. Furthermore, technological advancements in the market continuously drive the development of new and improved reagents.

ABO blood tests & Rh typing segment accounted for the largest share in the blood group typing industry in 2022, by test type.

The global blood group typing market is categorized into ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing based on test type. In 2022, the ABO blood tests & Rh typing segment held the largest share in the global market, categorized by test type. ABO blood tests and Rh typing are often conducted in tandem to provide a comprehensive blood typing profile. While ABO typing categorizes blood into four main groups (A, B, AB, and O), Rh typing determines the presence or absence of the Rh factor (Rh-positive or Rh-negative). This dual approach enhances compatibility assessment, covering major antigens influencing transfusion and transplantation outcomes.

Assay-based techniques segment accounted for the largest share in the blood group typing industry in 2022, by technique.

Based on techniques, the blood group typing market has been segmented into assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques. In 2022, the assay-based techniques segment accounted for the largest share of the global market. While the tube and slide methods have been foundational in blood group typing, the gel column and microplate methods have emerged as the largest and most sophisticated segments in this field. Their automation, increased sensitivity, objectivity in result interpretation, and high-throughput capabilities make them the preferred choice for modern blood banks, hospitals, and clinical laboratory settings.

North America accounted for the largest share of the blood group typing industry in 2022.

The blood group typing market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the blood group typing industry. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the blood group typing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Also, the high burden of chronic conditions on regional healthcare systems is another major driver for market growth.

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), and Immucor, Inc. (US). The market leadership of these players stems from their comprehensive product portfolios and expansive global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.

Scope of the Blood Group Typing Industry:

This report categorizes the blood group typing market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Consumables
  • Antisera Reagents
  • Anti-human Globulin Reagents
  • Red Blood Cell Reagents
  • Blood Bank Saline
• Instruments
• Services & Software

By Test Type

• ABO Blood Tests & Rh Typing
• Antibody Screening
• HLA Typing
• Cross-matching Tests
• Antigen Typing

By Technique

• Assay-based Techniques
• PCR-based and Microarray Techniques
• Massively Parallel Sequencing
• Other Techniques

By End User

• Hospitals
• Blood Banks
• Clinical Laboratories
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments of Blood Group Typing Industry:

• In June 2023, Quotient Limited (Switzerland) launched its ALBA products in the Netherlands and Sweden in addition to the following geographies: Austria, France, Germany, Greece, Hungary, Italy, Luxembourg, the Netherlands, Poland, Romania, Slovakia, and Sweden.
• In May 2023, Bio-Rad Laboratories, Inc. (US) launched the IH-500TM NEXT System, a fully automated system for ID cards. The IH-500 NEXT System not only reduces instrument downtime and increases laboratory productivity but also provides the flexibility and freedom to use high-performing Bio-Rad Reagent Red Blood Cells (RBCs), as well as the lab’s own RBCs or third-party Reagent RBCs.
• In March 2022, Quotient Limited (Switzerland) received the Conformité Européenne (CE) Mark for its MosaiQ Extended Immunohematology (IH) Microarray. The expanded array of features of MosaiQ allows for the comprehensive characterization of blood donor samples (blood typing and disease screening) through a single test procedure.
• In June 2023, Quotient Limited (Switzerland) and Transmedic Pte Ltd (Singapore) signed a distribution agreement, which will enable Transmedic to distribute Alba by Quotient and MosaiQ in five countries in Southeast Asia.
• In March 2023, With the acquisition of Immucor, Inc. (US), Werfen (Spain) expanded its presence as a company of reference in the specialized diagnostics market and grew its portfolio of diagnostic solutions for hospitals and clinical laboratories.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst